SCHEMBL4413412

SCHEMBL4413412

COc1cc2c(c(OC)c1)C(c1ccc(O)cc1)N(C(=O)CCC1CCCCC1)CC2

nearest known ligand 0.51

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
LMNA P02545 7/20 0.51
TP53 P04637 3/20 0.51
SMN1; SMN2 Q16637 1/20 0.50
MTNR1B P49286 1/20 0.44
GRIN2C Q14957 3/20 0.42
PARP1 P09874 1/20 0.42
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
MAPT P10636 1/20 0.41
FKBP1A P62942 4/20 0.41
MITF O75030 1/20 0.40
ALDH1A1 P00352 1/20 0.40
XBP1 P17861 1/20 0.40
HTT P42858 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
CYP2D6 P10635 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4423040 0.99 LMNA (0.51) LMNATP53SMN1; SMN2MTNR1BGRIN2C
SCHEMBL13972859 0.84 MTNR1B (0.45) MTNR1BGRIN2CPARP1FKBP1A
SCHEMBL4552686 0.84 MTNR1B (0.45) MTNR1BGRIN2CPARP1FKBP1A
SCHEMBL4418437 0.83 GRIN2C (0.46) LMNATP53MTNR1BGRIN2CPARP1
SCHEMBL4413283 0.82 MTNR1B (0.46) MTNR1BGRIN2CPARP1FKBP1A
SCHEMBL4420501 0.82 MTNR1B (0.51) LMNATP53SMN1; SMN2MTNR1BGRIN2C
SCHEMBL4414980 0.77 KMT2A (0.60) LMNATP53MTNR1BGRIN2CFKBP1A
SCHEMBL4416765 0.76 KMT2A (0.51) LMNAMTNR1BGRIN2CALDH1A1HTT
SCHEMBL4423041 0.75 GRIN2C (0.54) TP53MTNR1BGRIN2C
SCHEMBL4421006 0.75 ABCG2 (0.51) MTNR1BGRIN2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1663983-B1 N-SUBSTITUTED, 6,8-DIALKOXY-1,2,3,4-TETRAHYDRO-1H-ISOQUINOLINE AS POTASSIUM CHANNELS MODULATORS 4SC AG (DE) 2009-01-21 EP disclosed
EP-1663983-A1 N-SUBSTITUTED, 6,8-DIALKOXY-1,2,3,4-TETRAHYDRO-1H-ISOQUINOLINE AS POTASSIUM CHANNELS MODULATORS 4SC AG (DE) 2006-06-07 EP disclosed
US-20050070570-A1 Novel potassium channels modulators 4SC AG (DE) 2005-03-31 US disclosed
WO-2004113302-A1 N-SUBSTITUTED 6,8-DIALKOXY-1,2,3,4-TETRAHYDRO-1H-ISOQUINOLINE AS POTASSIUM CHANNELS MODULATORS 4SC AG (DE) 2004-12-29 WO disclosed
EP-1489071-A1 N-substituted, 3,4-dihydro-1H-isoquinoline as potassium channels modulators 4SC AG (DE) 2004-12-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050070570-A1 Novel potassium channels modulators HCN4, KCNA4, KCNN4 LMNA 4519/4885TP53 4194/4885SMN1; SMN2 4121/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.